 |
References
1: Savene® Orphan Medicinal Product Designation File.
2: Stanley A. Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P, eds. The cytotoxics handbook, 4th edn. Abingdon: Radcliffe Medical Press, 2002.
3. Langstein HN, Duman H, Seelig D, Butler CE, Evans GR. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002; 49(4):369-374.
4. Wang JJ, Cortes E, Sinks LF, Holland JF. Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 1971; 28(4):837-843.
5. Langer SW, et al. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol. 2006;57:125-8.
6. Llinares ME, et al. Toxicity to topical dimethyl sulfoxide in a pediatric patient with anthracycline extravasation. Pediatr Hematol Oncol. 2005;22:49-52.
7. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol. 1996;51:879-86.
8. Jensen PB, Sehested M. DNA topoisomerase II rescue by catalytic inhibitors. Biochem Pharmacol. 1997;54:755-9.
9. Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol. 1998;25(4) (Suppl 10):3-9.
10. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochem Biophys Acta. 1998;1400:155-71.
11. Hasinoff BB, Schroeder PE, Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol. 2003;64(3):670-8.
12. Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annals of Oncology. 2001;12:405-410.
13. Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000;6:3680-3686
14. Mouridsen HT et al. Treatment of anthracycline extravasation with Savene (dexrazoxane). Results from two prospective clinical multicenter studies. Annals of Oncology. Volume 18 Number 3 March 2007 pp 546-550
15. Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, Showel J et al. Adriamycin--an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973; 32(1):9-17.
16. Laughlin RA, Landeen JM, Habal MB. The management of inadvertent subcutaneous adriamycin infiltration. Am J Surg 1979; 137(3):408-412.
17. Barlock AL, Howser DM, Hubbard SM. Nursing management of adriamycin extravasation. Am J Nurs 1979; 79(1):94-96.
18. Pitkanen J, sko-Seljavaara S, Grohn P, Sundell B, Heinonen E, Appelqvist P. Adriamycin extravasation: surgical treatment and possible prevention of skin and soft-tissue injuries. J Surg Oncol 1983; 23(4):259-262.
19. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer 1982; 49(9):1796-1799.
20. Linder RM, Upton J. Prevention of extravasation injuries secondary to doxorubicin. Postgrad Med 1985; 77(4):105-9, 112, 114.
21. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13(11):2851-2855.
22. Langer SW et al., ICRF-187 (dexrazoxane) Inhibits Doxorubicin-Induced S.C. Necrosis in Mice: A New Strategy in Treating Accidental Anthracycline Extravasation. Proceedings 1999 ASCO meeting, Abstract no. 695.
23. Fontaine C, Noens L, Pierre P, de Grève J. Savene (dexrazoxane) use in clinical practice. Supp Care Cancer 2012
|
|
